$SLNO
SOLENO THERAPEUTICS INC

2015 Q1 Form 10-Q Financial Statement

#000119312515169136 Filed on May 04, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $22.00K $0.00
YoY Change -100.0%
Cost Of Revenue $18.00K $0.00
YoY Change
Gross Profit $4.000K $0.00
YoY Change
Gross Profit Margin 18.18%
Selling, General & Admin $1.552M $310.0K
YoY Change 400.65% -26.19%
% of Gross Profit 38800.0%
Research & Development $878.0K $372.0K
YoY Change 136.02% -46.86%
% of Gross Profit 21950.0%
Depreciation & Amortization $20.00K $10.00K
YoY Change 100.0% 0.0%
% of Gross Profit 500.0%
Operating Expenses $2.430M $684.0K
YoY Change 255.26% -38.93%
Operating Profit -$2.426M -$684.0K
YoY Change 254.68%
Interest Expense $1.000K $388.0K
YoY Change -99.74% -141.28%
% of Operating Profit
Other Income/Expense, Net -$9.225M -$8.000K
YoY Change 115212.5% -110.0%
Pretax Income -$11.65M -$830.0K
YoY Change 1303.61% -182.18%
Income Tax
% Of Pretax Income
Net Earnings -$11.65M -$834.0K
YoY Change 1297.0% -182.57%
Net Earnings / Revenue -52959.09%
Basic Earnings Per Share
Diluted Earnings Per Share -$8.381M -$597.1K
COMMON SHARES
Basic Shares Outstanding 6.769M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.530M $760.0K
YoY Change 1153.95%
Cash & Equivalents $9.529M $764.0K
Short-Term Investments
Other Short-Term Assets $280.0K $180.0K
YoY Change 55.56%
Inventory $206.0K
Prepaid Expenses
Receivables $8.000K $40.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.02M $990.0K
YoY Change 912.42%
LONG-TERM ASSETS
Property, Plant & Equipment $44.00K $40.00K
YoY Change 10.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $44.00K $40.00K
YoY Change 10.0%
TOTAL ASSETS
Total Short-Term Assets $10.02M $990.0K
Total Long-Term Assets $44.00K $40.00K
Total Assets $10.07M $1.030M
YoY Change 877.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $621.0K $90.00K
YoY Change 590.0%
Accrued Expenses $440.0K $220.0K
YoY Change 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $14.38M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.059M $14.69M
YoY Change -92.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.31M $1.220M
YoY Change 1564.75%
Total Long-Term Liabilities $20.31M $1.220M
YoY Change 1564.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.059M $14.69M
Total Long-Term Liabilities $20.31M $1.220M
Total Liabilities $21.37M $15.91M
YoY Change 34.32%
SHAREHOLDERS EQUITY
Retained Earnings -$81.99M
YoY Change
Common Stock $70.69M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.30M -$14.88M
YoY Change
Total Liabilities & Shareholders Equity $10.07M $1.030M
YoY Change 877.38%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$11.65M -$834.0K
YoY Change 1297.0% -182.57%
Depreciation, Depletion And Amortization $20.00K $10.00K
YoY Change 100.0% 0.0%
Cash From Operating Activities -$1.809M -$510.0K
YoY Change 254.71% -124.52%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$1.000K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $3.382M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -$1.809M -510.0K
Cash From Investing Activities -$1.000K 0.000
Cash From Financing Activities $3.382M 0.000
Net Change In Cash $1.572M -510.0K
YoY Change -408.24% -124.52%
FREE CASH FLOW
Cash From Operating Activities -$1.809M -$510.0K
Capital Expenditures $1.000K $0.00
Free Cash Flow -$1.810M -$510.0K
YoY Change 254.9% -124.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Line Of Credit
LineOfCredit
100000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
987000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70338000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
22000
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7511484 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
764000
CY2014Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
100000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7448389 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7448389 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q1 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.060 pure
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
438000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1059000
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
20311000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
621000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81989000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
70679000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-11303000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10067000
CY2015Q1 us-gaap Liabilities
Liabilities
21370000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9529000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
900000
CY2015Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
6500000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
260000
CY2015Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
35000
CY2015Q1 us-gaap Assets
Assets
10067000
CY2015Q1 us-gaap Inventory Net
InventoryNet
206000
CY2015Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
110000
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
10023000
CY2015Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
61000
CY2015Q1 capn Working Capital
WorkingCapital
9000000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1269000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6769106 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6769106 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
201000
CY2014Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
102000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1290000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
18296000
CY2014Q4 us-gaap Inventory Net
InventoryNet
109000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
8338000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.42
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-150000
CY2014Q4 us-gaap Assets
Assets
8396000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11000
CY2014Q1 us-gaap Interest Expense
InterestExpense
388000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
684000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
59141000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-11190000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
18000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8396000
CY2014Q4 us-gaap Liabilities
Liabilities
19586000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7957000
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
7900000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
252000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3949000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-13238000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-509000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
535685 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
77000
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-684000
CY2014Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
41000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-834000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
372000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-505000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-246000
CY2014Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
57000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7000
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
94000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4000
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
388000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
312000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31000
CY2015Q1 us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2014-09-29
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Capnia, Inc.
CY2015Q1 dei Trading Symbol
TradingSymbol
CAPN
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1999-08-25
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1809000
CY2015Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2015Q1 us-gaap Operating Leases Indemnification Agreements Description
OperatingLeasesIndemnificationAgreementsDescription
The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with modest increases in the following two years.
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets and the valuation of debt and equity instruments and stock-based compensation.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6965483 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001484565
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.67
CY2015Q1 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
The line of credit bears a fixed interest rate of 6.0% per annum simple interest.
CY2015Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-9200000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
2430000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
878000
CY2015Q1 us-gaap Revenues
Revenues
22000
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at March&#xA0;31, 2015 and December&#xA0;31, 2014. The Company expects this to continue.</p> </div>
CY2015Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.010 pure
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
530000
CY2015Q1 us-gaap Gross Profit
GrossProfit
4000
CY2015Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
102000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7000
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
97000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2426000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11651000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
401000
CY2015Q1 us-gaap Interest Expense
InterestExpense
1000
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
260000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1572000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6174000
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
62000
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
18000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
15000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3382000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
115000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1292000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
199000
CY2015Q1 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3050000
CY2015Q1 capn Operating Leases Expiration Date
OperatingLeasesExpirationDate
2015-05
CY2015Q1 capn Registration Rights Agreement Description And Terms
RegistrationRightsAgreementDescriptionAndTerms
The Company is required to comply with certain requirement to maintain the effectiveness of a registration statement for the offer and sale of these securities. The Warrant contracts further provide for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration
CY2015Q1 capn Cashless Exercise Of Warrant
CashlessExerciseOfWarrant
13000
CY2015Q1 capn Amendment Lease Agreement Period
AmendmentLeaseAgreementPeriod
2018-06
CY2015Q1 capn Reduction In Initial Public Offering Costs Payable
ReductionInInitialPublicOfferingCostsPayable
45000

Files In Submission

Name View Source Status
0001193125-15-169136-index-headers.html Edgar Link pending
0001193125-15-169136-index.html Edgar Link pending
0001193125-15-169136.txt Edgar Link pending
0001193125-15-169136-xbrl.zip Edgar Link pending
capn-20150331.xml Edgar Link completed
capn-20150331.xsd Edgar Link pending
capn-20150331_cal.xml Edgar Link unprocessable
capn-20150331_def.xml Edgar Link unprocessable
capn-20150331_lab.xml Edgar Link unprocessable
capn-20150331_pre.xml Edgar Link unprocessable
d915995d10q.htm Edgar Link pending
d915995dex311.htm Edgar Link pending
d915995dex312.htm Edgar Link pending
d915995dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending